SUPPORT HOTLINE (888) 901-2226
Donate Now

BRIEF TITLE: A Phase 1, Open-label, Dose Escalation Study Of Pf-04518600 As A Single Agent And In Combination With Pf-05082566 In Patients With Selected Locally Advanced Or Metastatic Carcinomas

A Phase 1, Open-label, Dose Escalation Study Of Pf-04518600 As A Single Agent And In Combination With Pf-05082566 In Patients With Selected Locally Advanced Or Metastatic Cancers


  • Org Study ID: B0601002
  • Secondary ID: 2014-004107-75,B0601002
  • NCT ID: NCT02315066
  • NCT Alias:
  • Sponsor: Pfizer - Industry
  • Source: Pfizer

Brief Summary

To assess the safety and tolerability at increasing dose levels of PF-04518600 alone or in combination wtih PF-05082566 in patients with select advanced or metastatic carcinoma in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.

Overal Status Start Date Phase Study Type
Recruiting April 23, 2015 Phase 1 Interventional

Primary Outcomes:

Primary Outcome 1 - Measure: Number of participants with Dose-limiting toxicities (DLT) [Dose Escalation]

Primary Outcome 1 - Time Frame: Day 1 up to Day 28

Primary Outcome 2 - Measure: Overall safety profile [Dose Expansion]

Primary Outcome 2 - Time Frame: Day 1 up to Day 28

Condition:

  • Neoplasms

Eligibility

Criteria:
Inclusion Criteria:

- Part A1 only: Patients with histological or cytological diagnosis of HNSCC, HCC,
melanoma, or clear cell RCC who progressed on or are intolerant to standard therapy,
for which no standard therapy is available or who decline standard therapy.

- Part A2 only: Patients with histological or cytological diagnosis of HCC who have had
0 to 2 prior lines of systemic therapy (progressed or intolerant to approved HCC
standard of care treatment).

- Part B1 only: Patients with histological or cytological diagnosis of NSCLC, HNSCC,
melanoma, urothelial bladder carcinoma (including renal pelvis, ureters, urinary
bladder, and urethra), gastric or squamous cell carcinoma of the uterine cervix who
progressed on or are intolerant to standard therapy, for which no standard therapy is
available, or who decline standard therapy.

- Part B2

Arm 1 only:

1. Ocular melanoma; and have received no more than one line of systemic therapy for
metastatic disease. Patients must not have received immune modifying agents (eg. anti
PD-L1, anti PD-1, anti CTLA4, TNF agonist, etc.) for metastatic disease, or

2. Cutaneous/acral melanoma; and have 1) only previously received systemic therapy for
advanced/metastatic disease with the following therapies: BRAF and MEK inhibitors,
anti PD-L1, anti PD-1, or anti-CTLA4 and 2) have received checkpoint inhibitor (anti
PD-L1, anti PD-1, or anti-CTLA4) based treatment as most recent line of therapy on
which disease progressed, as long as progression did not occur in the first 3 months
of receiving checkpoint inhibitor treatment.

Arm 2 only:

- Histological or cytological diagnosis of NSCLC. Patients must have 1) previously
received prior anti-PD-L1 or anti-PD-1 mAb as most recent therapy, AND 2) did not have
progressive disease as best overall response on recent PD-L1/PD-1 therapy (ie, stable
disease 3 months, PR, or CR), AND 3) who subsequently progressed on anti-PD-L1 or
anti-PD-1 mAb.

- Performance Status of 0 or 1 - Adequate bone marrow, kidney and liver function

Exclusion Criteria:

- Brain metastases requiring steroids

- Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of
study treatment start (6 weeks for mitomycin C or nitrosoureas)

- Active and clinically significant bacterial, fungal, or viral infection

- History of active autoimmune disorders

- History of immune-mediated adverse events requiring immunosuppressive therapy or were
grade 3 or higher related to prior immune-modulatory therapy

- Prior treatment with an OX40 agonist and 4-1BB agonist (for Part B1/B2)

- Prior anthracycline treatment and at risk of cardiac failure (New York Heart
Association Class 2)
Show More

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

Official Information

Name: Pfizer CT.gov Call Center

Role: Study Director

Affiliation: Pfizer

Overall Contact

Name: Pfizer CT.gov Call Center

Phone: 1-800-718-1021

Email: ClinicalTrials.gov_Inquiries@pfizer.com

Link: To obtain contact information for a study center near you, click here.

Locations

Facility Status Contact
Clinical Research Unit
Los Angeles, California 90024
United States
Recruiting
The Angeles Clinic And Research Institute, A Cedars-Sinai Affiliate
Los Angeles, California 90025
United States
Recruiting
Keck Hospital of USC
Los Angeles, California 90033
United States
Recruiting
LAC+USC Medical Center
Los Angeles, California 90033
United States
Recruiting
USC/Norris Comprehensive Cancer Center
Los Angeles, California 90033
United States
Recruiting
Ronald Reagan UCLA Medical Center
Los Angeles, California 90095-6984
United States
Recruiting
Ronald Regan Medical Center
Los Angeles, California 90095
United States
Recruiting
UCLA Hematology-Oncology Clinic
Los Angeles, California 90095
United States
Recruiting
Hoag Memorial Hospital Presbyterian
Newport Beach, California 92663
United States
Recruiting
Medical Imaging Center of Southern California, Inc.
Santa Monica, California 90403
United States
Recruiting
Santa Monica UCLA Hematology & Oncology Clinic
Santa Monica, California 90404
United States
Recruiting
The Angeles Clinic And Research Institute, A Cedars-Sinai Affiliate
Santa Monica, California 90404
United States
Recruiting
UConn Health, Pharmacy
Farmington, Connecticut 06030-2205
United States
Recruiting
UConn Health, Neag Comprehensive Cancer Center
Farmington, Connecticut 06030
United States
Recruiting
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida 33612
United States
Recruiting
Massachusetts General Hospital (MGH)
Boston, Massachusetts 02114
United States
Recruiting
Brigham & Women's Hospital (BWH)
Boston, Massachusetts 02115
United States
Recruiting
Beth Israel Deaconess Medical Center (BIDMC)
Boston, Massachusetts 02215
United States
Recruiting
Dana-Farber Cancer Institute (DFCI)
Boston, Massachusetts 02215
United States
Recruiting
Columbia University Medical Center - Herbert Irving Pavilion
New York, New York 10032
United States
Recruiting
CUMC Research Pharmacy
New York, New York 10032
United States
Recruiting
Methodist Hospital-Pathology
Houston, Texas 77030
United States
Recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas 77030
United States
Recruiting
Seattle Cancer Care Alliance (Drug Shipment Address)
Seattle, Washington 98109
United States
Recruiting
Seattle Cancer Care Alliance
Seattle, Washington 98109
United States
Recruiting
University of Washington Medical Center
Seattle, Washington 98195
United States
Recruiting
Centre D'Investigation Clinique (CIC)
Paris, 75013
France
Recruiting
Groupe hospitalier Pitie Salpetriere
Paris, 75013
France
Recruiting
Laboratory research biomedical (LRBM)
Paris, 75013
France
Recruiting
Institut Gustave Roussy- Pharmacie-Unite Essais Cliniques
Villejuif, 94805
France
Recruiting
Institut Gustave Roussy
Villejuif, 94805
France
Recruiting
National Cancer Center Hospital East
Kashiwa, Chiba 277-8577
Japan
Recruiting
The Netherlands Cancer Institute
Amsterdam, 1066 CX
Netherlands
Recruiting
Slotervaart Hospital/Antoni van Leeuwenhoek
Amsterdam, 1066 EC
Netherlands
Recruiting
Erasmus MC Cancer Institute
Rotterdam, 3015 AA
Netherlands
Recruiting
Erasmus MC
Rotterdam, 3015 AE
Netherlands
Recruiting